Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Emerging Markets Earnings Roundup: Merck And Novo Nordisk (Part 5)

This article was originally published in PharmAsia News

Executive Summary

In this earnings round up, we zoom in on Merck and Novo Nordisk performance in emerging markets for 2012.


Related Content

With Odanacatib Filing Pushed Back, Merck Reports Flat Top-Line Growth In 2012
Once-Weekly Insulin Added To Novo Nordisk’s Clinical Pipeline
Victoza Approved In China: Novo Nordisk Gears Up To Conquer China's Diabetes Market
Merck Sharp & Dohme Launches Januvia In China To Join Race In Second-largest Diabetes Market


Related Companies

Related Deals




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts